News

AS Effects on Shoulder Often Are Overlooked


 

GLASGOW, SCOTLAND — Shoulder involvement is often overlooked in ankylosing spondylitis, despite patients' reports that upper body pain interferes with their daily activities, Dr. Charlotte E. Page reported in a poster session at the annual meeting of the British Society for Rheumatology.

Among a group of 31 ankylosing spondylitis (AS) patients attending a 2-week physiotherapy program who responded to questionnaires about their symptoms, 12 reported current shoulder pain, while 10 patients reported experiencing shoulder pain in the past, reported Dr. Page of the rheumatology department of University Hospital of Wales, Cardiff. The patients, aged 17–62 years, had a mean AS duration of 19 years.

Among patients with current shoulder pain, four reported bilateral symptoms, and nine indicated that their daily activities were affected. Among those with previous pain, three study patients reported that their shoulder involvement continued to interfere with their daily activities, noted Dr. Page.

The reported prevalence of shoulder pain among the general population is approximately 12%, and estimates among those with AS range from 7% to 33%, she noted. “Our prevalence of 39% is slightly higher, probably reflecting the type of patients who attend intensive physiotherapy programs.”

Only 10 of the 22 patients who had either current or past shoulder pain had undergone one or more radiologic investigations. Eight had been evaluated with plain radiographs, three with ultrasound, and three with MRI arthrograms.

Among the eight patients who had received one or more corticosteroid injections to the shoulder region, five reported still having shoulder pain and six reported still experiencing symptoms that interfered with daily activities. Among the seven who had received physiotherapy directed at their shoulder symptoms, five continued to experience pain.

Specific physiotherapy and corticosteroid injections had therefore been given to only 32% and 36% of patients, respectively, and had not alleviated the symptoms in the majority, she noted.

Moreover, a total of 26 patients reported peripheral joint involvement other than the shoulder. Despite this, only six patients received disease-modifying antirheumatic drugs or anti-tumor necrosis factor-α therapy, which suggests an underappreciation of the extent of AS patients' peripheral joint pain, according to Dr. Page.

Much of the shoulder involvement was rotator cuff tendonitis, which can be imaged and treated, Dr. Page said in an interview. Patients should be asked specifically about this, she said.

“We all know about their hip pain but we seem to forget about the top half” of the body, she said.

Recommended Reading

CV Risks Unchanged by Infliximab Therapy
MDedge Rheumatology
Glucocorticoid Use May Elevate Tuberculosis Risk Fivefold
MDedge Rheumatology
Clinical Capsules
MDedge Rheumatology
Lack of 'Trio' Families Thwarts RA Gene Studies
MDedge Rheumatology
Rare Disease Offers Pediatric Rheumatology Insights : Report details genetic mutation in the joint condition camptodactyly-arthropathy-coxa vara-pericarditis.
MDedge Rheumatology
Gelfoam Interposition Spares the Tendon in Osteoarthritis
MDedge Rheumatology
Resistance/Motor Task IDs Carpal, Cubital Tunnel Syndromes
MDedge Rheumatology
High CRP Levels, ESR Warrant Infliximab Add-On
MDedge Rheumatology
Drugs for Rheumatoid Diseases Trigger Skin Woes : Discontinuing the troublesome medication may not always be possible, necessitating clinical ingenuity.
MDedge Rheumatology
Apheresis Healed Refractory Pyoderma Gangrenosum Lesions
MDedge Rheumatology